$EOLS
Evolus Inc

2023 Q4 Form 10-Q Financial Statement

#000157056223000115 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $61.00M $50.02M
YoY Change 39.76% 47.55%
Cost Of Revenue $19.27M $15.43M
YoY Change 44.13% 14.39%
Gross Profit $41.73M $34.59M
YoY Change 37.83% 69.47%
Gross Profit Margin 68.41% 69.15%
Selling, General & Admin $43.06M $43.33M
YoY Change 17.23% 24.53%
% of Gross Profit 103.18% 125.27%
Research & Development $6.808M $1.587M
YoY Change 405.04% 15.33%
% of Gross Profit 16.31% 4.59%
Depreciation & Amortization $1.373M $1.311M
YoY Change 33.69% 42.5%
% of Gross Profit 3.29% 3.79%
Operating Expenses $51.24M $44.92M
YoY Change 31.03% 24.18%
Operating Profit -$9.510M -$13.44M
YoY Change 7.73% -24.9%
Interest Expense -$3.784M $3.786M
YoY Change 48.16% 61.59%
% of Operating Profit
Other Income/Expense, Net $694.0K $21.00K
YoY Change 726.19% -133.87%
Pretax Income -$11.73M -$16.90M
YoY Change -10.54% -16.61%
Income Tax $106.0K $24.00K
% Of Pretax Income
Net Earnings -$11.83M -$16.92M
YoY Change -10.13% -16.54%
Net Earnings / Revenue -19.4% -33.83%
Basic Earnings Per Share -$0.30
Diluted Earnings Per Share -$0.21 -$0.30
COMMON SHARES
Basic Shares Outstanding 57.15M shares 56.97M shares
Diluted Shares Outstanding 57.02M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $62.84M $38.70M
YoY Change 16.53% -40.98%
Cash & Equivalents $62.84M $38.69M
Short-Term Investments
Other Short-Term Assets $2.356M $1.569M
YoY Change 40.41% -62.93%
Inventory $11.00M $17.63M
Prepaid Expenses $5.700M $3.655M
Receivables $30.53M $30.46M
Other Receivables $0.00 $0.00
Total Short-Term Assets $112.4M $92.00M
YoY Change 11.53% -20.65%
LONG-TERM ASSETS
Property, Plant & Equipment $2.087M $2.130M
YoY Change -20.22% 13.18%
Goodwill $21.21M $21.21M
YoY Change 0.0% 0.0%
Intangibles $47.11M $46.51M
YoY Change -3.06% -5.3%
Long-Term Investments
YoY Change
Other Assets $409.0K $222.0K
YoY Change -85.46% -90.85%
Total Long-Term Assets $76.58M $75.97M
YoY Change -0.78% -1.04%
TOTAL ASSETS
Total Short-Term Assets $112.4M $92.00M
Total Long-Term Assets $76.58M $75.97M
Total Assets $189.0M $168.0M
YoY Change 6.19% -12.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.271M $11.76M
YoY Change -52.2% 37.32%
Accrued Expenses $33.81M $26.71M
YoY Change 36.38% -10.61%
Deferred Revenue $11.03M $8.780M
YoY Change 22.44% -13.82%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $48.29M $48.54M
YoY Change 3.83% -5.33%
LONG-TERM LIABILITIES
Long-Term Debt $120.4M $95.10M
YoY Change 67.45% 32.61%
Other Long-Term Liabilities $41.01M $43.70M
YoY Change -0.16% 7.93%
Total Long-Term Liabilities $161.4M $138.8M
YoY Change 42.86% 23.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $48.29M $48.54M
Total Long-Term Liabilities $161.4M $138.8M
Total Liabilities $209.7M $187.3M
YoY Change 31.48% 14.58%
SHAREHOLDERS EQUITY
Retained Earnings -$559.0M -$547.1M
YoY Change 12.4% 13.02%
Common Stock $1.000K $1.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$20.69M -$19.37M
YoY Change
Total Liabilities & Shareholders Equity $189.0M $168.0M
YoY Change 6.19% -12.84%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$11.83M -$16.92M
YoY Change -10.13% -16.54%
Depreciation, Depletion And Amortization $1.373M $1.311M
YoY Change 33.69% 42.5%
Cash From Operating Activities $813.0K -$920.0K
YoY Change -109.27% -94.6%
INVESTING ACTIVITIES
Capital Expenditures $361.0K $540.0K
YoY Change -74.05% -160.07%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$361.0K -$540.0K
YoY Change -74.05% -39.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 23.52M -1.420M
YoY Change -1651.58% 87.09%
NET CHANGE
Cash From Operating Activities 813.0K -920.0K
Cash From Investing Activities -361.0K -540.0K
Cash From Financing Activities 23.52M -1.420M
Net Change In Cash 23.97M -2.880M
YoY Change -305.24% -84.61%
FREE CASH FLOW
Cash From Operating Activities $813.0K -$920.0K
Capital Expenditures $361.0K $540.0K
Free Cash Flow $452.0K -$1.460M
YoY Change -104.45% -90.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001570562
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
57150722 shares
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2616000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1947000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
48597000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
21208000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2813000 usd
CY2022Q4 us-gaap Assets
Assets
177983000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8935000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24794000 usd
CY2023Q3 us-gaap Litigation Reserve Current
LitigationReserveCurrent
0 usd
CY2022Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
5000000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1363000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1320000 usd
CY2023Q3 eols Contingent Royalty Obligation Payableto Related Party Current
ContingentRoyaltyObligationPayabletoRelatedPartyCurrent
8704000 usd
CY2022Q4 eols Contingent Royalty Obligation Payableto Related Party Current
ContingentRoyaltyObligationPayabletoRelatedPartyCurrent
6460000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
48540000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46509000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4983000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1224000 usd
CY2023Q3 us-gaap Contractual Obligation
ContractualObligation
38700000 usd
CY2022Q4 us-gaap Contractual Obligation
ContractualObligation
39850000 usd
CY2023Q3 us-gaap Secured Long Term Debt
SecuredLongTermDebt
95094000 usd
CY2022Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
71879000 usd
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
22000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
22000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
187339000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57092480 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56260570 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56260570 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
528385000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
516129000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-606000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-337000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-497294000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
18499000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
167971000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
177983000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33899000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
141086000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
104970000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34794000 usd
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1376000 usd
CY2022Q3 eols Research And Development In Process1
ResearchAndDevelopmentInProcess1
0 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1216000 usd
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
38000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
3786000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
2343000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-62000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20264000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-20276000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-203000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20479000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56808333 shares
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53922000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22448000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
18852000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3902000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1678000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
100802000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
159484000 usd
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-547148000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-19368000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
42289000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
42517000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
121886000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
105111000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4176000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3394000 usd
eols Research And Development In Process1
ResearchAndDevelopmentInProcess1
4441000 usd
eols Research And Development In Process1
ResearchAndDevelopmentInProcess1
2000000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-5132000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-3946000 usd
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
920000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3760000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2695000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
51796000 usd
us-gaap Costs And Expenses
CostsAndExpenses
181684000 usd
us-gaap Costs And Expenses
CostsAndExpenses
159663000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17897000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-40598000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-54693000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
569000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
42000 usd
us-gaap Interest Expense
InterestExpense
9757000 usd
us-gaap Interest Expense
InterestExpense
6466000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-93000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49784000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-61210000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
70000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38000 usd
us-gaap Net Income Loss
NetIncomeLoss
-49854000 usd
us-gaap Net Income Loss
NetIncomeLoss
-61248000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-269000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-368000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50123000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61616000 usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55997545 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55997545 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
81876000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2959000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-17501000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-103000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
67248000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
167000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2979000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23471000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-62000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
46861000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
355000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2483000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-20276000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-203000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
29220000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4171000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-18140000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-52000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6963000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
60000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4596000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16923000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-138000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-19368000 usd
us-gaap Net Income Loss
NetIncomeLoss
-49854000 usd
us-gaap Net Income Loss
NetIncomeLoss
-61248000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3760000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2695000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
12061000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8421000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1354000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
590000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
573000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
843000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
805000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-15000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
5132000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3946000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9370000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7626000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
654000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15283000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-247000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1426000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-110000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2300000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4789000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2338000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1919000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-110000 usd
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
5000000 usd
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
15000000 usd
eols Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-748000 usd
eols Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-723000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34821000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-76138000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
264000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
752000 usd
us-gaap Payments For Software
PaymentsForSoftware
1002000 usd
us-gaap Payments For Software
PaymentsForSoftware
796000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1266000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1548000 usd
eols Payments Of Contingent Royalty Obligation
PaymentsOfContingentRoyaltyObligation
4038000 usd
eols Payments Of Contingent Royalty Obligation
PaymentsOfContingentRoyaltyObligation
3169000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25000000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
38000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
eols Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan
ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan
195000 usd
eols Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan
ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan
539000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21119000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2630000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-269000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-368000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15237000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-80684000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53922000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146256000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38685000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65572000 usd
us-gaap Interest Paid Net
InterestPaidNet
8908000 usd
us-gaap Interest Paid Net
InterestPaidNet
5651000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
95000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
70000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4550000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13440000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16923000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34821000 usd
eols Research And Development In Process1
ResearchAndDevelopmentInProcess1
4441000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38685000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-547148000 usd
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
7566000 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2450000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2050000 usd
CY2023Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1012000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1354000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements, inventory valuations and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company’s actual results could differ materially from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an agreement (the “Daewoong Agreement”) with Daewoong Pharmaceutical Co. Ltd. (“Daewoong”), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company’s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019 and in Canada through its distribution partner in October 2019. The Company also began commercially launching Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe in September 2022 and, as such, has a limited history of sales in those markets. If any previously granted approval to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">retracted or the Company is denied approval or approval is delayed by regulators in any other jurisdictions, it may have a material adverse impact on the Company’s business and its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company’s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disruption and volatility in the global capital markets, including caused by other events, such as public health crises, increased inflation and rising interest rates, and geopolitical conflicts, including the military conflict between Russia and Ukraine and the ongoing conflict in the Middle East, may increase the Company’s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. Substantially all of the Company’s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company’s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for credit losses based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers’ ability to pay.</span></div>
CY2023Q3 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 reporting_unit
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2022Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
CY2023Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8780000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9011000 usd
eols Rebates And Coupons Credits And Payments
RebatesAndCouponsCreditsAndPayments
22264000 usd
eols Rebates And Coupons Credits And Payments
RebatesAndCouponsCreditsAndPayments
17341000 usd
eols Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability
PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability
22495000 usd
eols Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability
PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability
15087000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
7751000 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
1057000 usd
eols Accounts Receivable Allowance For Credit Loss Writeoff After Recovery
AccountsReceivableAllowanceForCreditLossWriteoffAfterRecovery
955000 usd
CY2022Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
623000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1363000 usd
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
392000 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
477000 usd
CY2022Q2 eols Research And Development In Process1
ResearchAndDevelopmentInProcess1
2000000 usd
eols Research And Development In Process1
ResearchAndDevelopmentInProcess1
2000000 usd
CY2023Q2 eols License Supply And Distribution Agreement Minimum Milestone Payment
LicenseSupplyAndDistributionAgreementMinimumMilestonePayment
16200000 eur
CY2023Q2 eols License Supply And Distribution Agreement Initial Payment In Connection With Agreement
LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement
4100000 eur
CY2023Q2 eols License Supply And Distribution Agreement Initial Payment Due Period
LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod
P30D
CY2023Q2 eols License Supply And Distribution Agreement Annual Payment Year One
LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne
1600000 eur
CY2023Q2 eols License Supply And Distribution Agreement Annual Payment Year Two
LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo
4100000 eur
CY2023Q2 eols License Supply And Distribution Agreement Annual Payment Year Three
LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree
3200000 eur
CY2023Q2 eols License Supply And Distribution Agreement Annual Payment Year Four
LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour
3200000 eur
CY2023Q2 eols Research And Development In Process1
ResearchAndDevelopmentInProcess1
4441000 usd
CY2023Q2 eols License Supply And Distribution Agreement Initial Term
LicenseSupplyAndDistributionAgreementInitialTerm
P15Y
CY2023Q2 eols License Supply And Distribution Agreement Renewal Term
LicenseSupplyAndDistributionAgreementRenewalTerm
P5Y
eols Research And Development In Process1
ResearchAndDevelopmentInProcess1
4441000 usd
CY2023Q3 us-gaap Litigation Reserve Current
LitigationReserveCurrent
0 usd
CY2022Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
5000000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
70000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38000 usd
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
47081000 usd
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
45415000 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
46310000 usd
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
44740000 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
1479000 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
1114000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
4038000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
3169000 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1802000 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1216000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-5132000 usd
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-3946000 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
47404000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68631000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
46505000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
21208000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
21208000 usd
CY2023Q3 eols Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
89839000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
22126000 usd
CY2023Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
67713000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
67712000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19115000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
48597000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
21208000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
21208000 usd
CY2022Q4 eols Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
88920000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19115000 usd
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
69805000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1113000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3731000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2996000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2955000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2955000 usd
CY2023Q3 eols Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
32755000 usd
CY2023Q3 us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
349000 usd
CY2022Q3 us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
531000 usd
us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
919000 usd
us-gaap Capitalized Computer Software Additions
CapitalizedComputerSoftwareAdditions
938000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1053000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
838000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3005000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2454000 usd
CY2023Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2999000 usd
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2618000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9466000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7454000 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8780000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9011000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5468000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5711000 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
26713000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
24794000 usd
CY2023Q2 eols Debt Instrument Number Of Installments
DebtInstrumentNumberOfInstallments
2 installment
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
33333000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
66667000 usd
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
100000000 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4906000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
95094000 usd
CY2019Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2023Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P60M
CY2023Q3 eols Lessee Operating Lease Abatement Period
LesseeOperatingLeaseAbatementPeriod
P3M
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4550000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4550000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
286000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
273000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
833000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
811000 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
48000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
18000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
110000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
65000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
334000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
291000 usd
us-gaap Lease Cost
LeaseCost
943000 usd
us-gaap Lease Cost
LeaseCost
876000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.110
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.094
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
332000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1377000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1053000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1451000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1502000 usd
CY2023Q3 eols Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
3299000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9014000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2668000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6346000 usd
CY2023Q3 us-gaap Purchase Obligation
PurchaseObligation
1762000 usd
CY2020Q4 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
2 complaint
CY2021Q4 eols Loss Contingency Number Defendants Officers
LossContingencyNumberDefendantsOfficers
3 officer
CY2020Q4 us-gaap Loss Contingency Number Of Plaintiffs
LossContingencyNumberOfPlaintiffs
2 plaintiff
CY2022Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 usd
CY2023Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57092480 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57092480 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
4361291 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
0.040
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
452244 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P10Y
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4596000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2483000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12061000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8421000 usd
CY2021Q1 eols Loss Contingency Settlement Agreement Manufacturing License Period
LossContingencySettlementAgreementManufacturingLicensePeriod
P21M
CY2021Q1 eols Share Issuance Agreement Percentage Of Share Dispose Per Year Period One
ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne
0.25
CY2021Q1 eols Share Issuance Agreement Percentage Of Share Dispose Per Year Period Two
ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo
0.50
CY2021Q1 eols Share Issuance Agreement Percentage Of Share Dispose Per Year Period Three
ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree
0.75
CY2021Q1 eols Registration Rights Agreement Selling Period
RegistrationRightsAgreementSellingPeriod
P3M
CY2023Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2999000 usd
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
2618000 usd
CY2022Q4 us-gaap Litigation Reserve
LitigationReserve
5000000 usd
CY2023Q3 eols Payments For Inventory
PaymentsForInventory
8785000 usd
eols Payments For Inventory
PaymentsForInventory
36537000 usd
CY2022Q3 eols Payments For Inventory
PaymentsForInventory
14238000 usd
eols Payments For Inventory
PaymentsForInventory
40509000 usd

Files In Submission

Name View Source Status
eols-20230930_def.xml Edgar Link unprocessable
eols-20230930_pre.xml Edgar Link unprocessable
eols-20230930_cal.xml Edgar Link unprocessable
0001570562-23-000115-index-headers.html Edgar Link pending
0001570562-23-000115-index.html Edgar Link pending
0001570562-23-000115.txt Edgar Link pending
0001570562-23-000115-xbrl.zip Edgar Link pending
a93023ex102-tomokoemployme.htm Edgar Link pending
eols-20230930.htm Edgar Link pending
eols-20230930.xsd Edgar Link pending
exhibit311q32023.htm Edgar Link pending
exhibit312q32023.htm Edgar Link pending
exhibit321q32023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
eols-20230930_lab.xml Edgar Link unprocessable
eols-20230930_htm.xml Edgar Link completed
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending